focus -WSS

focus

author：focus 2025-09-27 23:02:26 - browse：985

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Physician groups backed by private equity giant lobby on mergers

WSS

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Sage hopes for a blockbuster in antidepressant now before FDA

FDA's Woodcock to retire early next year

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

entertainment

focus

explore

Medicare details structure of new drug price negotiation program

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Moonlake's readout produced a cash windfall. Risks remain

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

BioMarin wins approval for gene therapy to treat hemophilia A

A daunting task: navigating dual Medicare, Medicaid eligibility

BioMarin wins approval for gene therapy to treat hemophilia A

David Sabatini, ex

In age of alternative facts, a scholarly course on calling out crap

Scientists inch closer to single

leisure time

No plane should take off without an EpiPen onboard

A daunting task: navigating dual Medicare, Medicaid eligibility

PBM reforms clear House panel

Childhood cancer progress stalls for Black, Hispanic kids: Report

‘Oppenheimer’ and the risks of AI in health care

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

explore

focus

explore

explore